Hostname: page-component-76fb5796d-dfsvx Total loading time: 0 Render date: 2024-04-26T10:29:02.985Z Has data issue: false hasContentIssue false
  • English
  • Français

Diphenylhydantoin and Pulmonary Function

Published online by Cambridge University Press:  18 September 2015

Ronald J. Smith ,
Godfrey C. W. Man ,
S. F. Paul Man  and
Donald R. McLean
Ronald J. Smith
Affiliation:
Department of Medicine, Divisions of Neurology and Pulmonary Medicine, University of Alberta, Edmonton
Godfrey C. W. Man
Affiliation:
Department of Medicine, Divisions of Neurology and Pulmonary Medicine, University of Alberta, Edmonton
S. F. Paul Man
Affiliation:
Department of Medicine, Divisions of Neurology and Pulmonary Medicine, University of Alberta, Edmonton
Donald R. McLean*
Affiliation:
Department of Medicine, Divisions of Neurology and Pulmonary Medicine, University of Alberta, Edmonton
*
Division of Neurology, 9-101 Clinical Sciences, University of Alberta, Edmonton, Alberta, T6G 2G3, Canada.
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Thirty-nine epileptic patients underwent pulmonary function testing. Twenty-one of these patients, ranging in age from 16 to 44 years, had taken diphenylhydantoin (DPH) for 2 to 17 years. Eighteen patients, who had taken other anticonvulsants for similar time periods served as controls. Five patients in the DPH group had lung volume abnormalities, four had abnormal airway function, and five had abnormalities of alveolar gas mixing. One patient in the control group had lung volume abnormalities, two had abnormal airway function, and five had abnormalities of alveolar gas mixing. Statistical analysis revealed no significant differences between the groups, or between either group and predicted values.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 6 , Issue 1 , February 1979 , pp. 21 - 25
Copyright
Copyright © Canadian Neurological Sciences Federation 1979

References

Bates, D. V., Boncot, H.G., Dormer, A. E. (1955). The pulmonary diffusing capacity in normal subjects. J. Physiol. (Lond.) 129: 237.CrossRefGoogle ScholarPubMed
Bates, D. V., Woolf, C. R., Paul, G. I. (1962). A report on the first two stages of the coordinated study of the chronic bronchitis in the Department of Veterans Affairs, Canada, Can. Med. Serv. 18: 211–303.Google ScholarPubMed
Bayer, A. S., Torgan, S. R., Pitchman, S. E., Guze, L. B. (1976). Dilantin toxicity: Miliary pulmonary infiltrates and hypoxe-mia. Ann. Intern. Med. 85: 475–476.CrossRefGoogle Scholar
Black, L. F., Offord, K., Hyatt, R. E. (1974). Variability in the maximal expiratory flow volume curve in asymptomatic smokers and in non-smokers. Am. Rev. Respir. Dis. 110: 282–292.CrossRefGoogle Scholar
Boren, H. G., Kory, R. C., Snyer, J. C. (1966). The Veterans Administration-Army cooperative study of pulmonary function. Am. J. Med. 41: 96–114.CrossRefGoogle Scholar
Buist, A. S., Ross, B. B. (1973). Predicted values for closing volumes using a modified single breath nitrogen test. Am. Rev. Respir. Dis. 107: 744–752.Google ScholarPubMed
Dubois, A.B., Botelho, S.Y., Comroe, J. H. (1956). A new method for measuring airway resistance in man using a body plethysmograph; values in normal subjects and in patients with respiratory disease. J. Clin. Invest. 35: 327–335.CrossRefGoogle ScholarPubMed
Hazlett, D. R., Ward, G. W., Madison, D. S. (1974). Pulmonary function loss in diphenylhydantoin therapy. Chest 66: 660–664.CrossRefGoogle ScholarPubMed
Livingston, S., Whitehouse, D., Pauli, L. L. (1961). Study of the effects of diphenylhydantoin sodium on the lungs. N. Engl. J. Med., 264: 648–651.CrossRefGoogle ScholarPubMed
Low, N. L., Yahr, M. D. (1960). The lack of pulmonary fibrosis in patients receiving diphenylhydantoin. JAMA 174: 1201–1202.CrossRefGoogle ScholarPubMed
Macnamera, J., Prime, F. J., Sinclair, J. D. (1959). An assessment of the steady state carbon monoxide method of estimating pulmonary diffusion capacity. Thorax 14: 166.CrossRefGoogle Scholar
Merrit, H. H., Putnam, T. J. (1938). Sodium diphenylhydantoinate in the treatment of convulsive disorders. JAMA 111: 1068–1133.CrossRefGoogle Scholar
Moore, M. T. (1959). Pulmonary changes in hydantoin therapy. JAMA 171: 1328–1333.CrossRefGoogle ScholarPubMed
Sparberg, M. (1963). Diagnostically confusing complications of Diphenylhydantoin therapy. Ann. Intern. Med. 59: 914–930.CrossRefGoogle ScholarPubMed